Lead Product(s): Mirtazapine
Therapeutic Area: Nutrition and Weight Loss
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Dechra Pharmaceuticals Manufacturing
Deal Size: Undisclosed Upfront Cash: $43.0 million
Deal Type: Divestment March 16, 2020
The company has entered into a transaction for the sale of Mirataz® to Dechra Pharmaceuticals PLC.